AR and glycogen storage disease VI: Observations that AR-targeting agents (such as abiraterone and enzalutamide) improve overall and metastasis-free survival in patients with hormone-sensitive and nonmetastatic disease, respectively, suggests that earlier intense inhibition of AR may further improve outcomes4–6.